BioWorld

May 13, 2005

View Archived Issues

Cephalon's Parkinson's Study Stopped; No Benefit Showed

Cephalon Inc. called a halt to a late-stage study of a partnered Parkinson's disease drug, CEP-1347, as interim results revealed a lack of clinical benefit. (BioWorld Today) Read More

CuraGen Partner Signs CRADA; Subsidiary 454 Enters $62M Deal

Read More

Tranzyme's Story: Early Stage Firm Brings In $32M Financing

Read More

Spherics Gets $26M To Push Bioadhesive Drug Delivery

Read More

Other News To Note

Read More